MAPK14 and hepatocellular carcinoma: While blocking pErk in the pathway did not significantly reduce sorafenib resistance, knocking down phosphorylated mitogen-activated protein kinase 14 (pMAPK14) was found to rescue the efficacy of sorafenib in HBV-expressing hepatoma cells [230].